Announcements Trials
Browse Landscape

Phase

Phase 3 39Phase 2 18Phase 1 12Phase NA 10Phase 4 5Phase 2/3 3Phase 1/2 3Phase EARLY_PHASE1 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 699Breast Neoplasms 629Neoplasms 582Leukemia, Myeloid, Acute 481Colorectal Neoplasms 455Multiple Myeloma 444Melanoma 424Prostatic Neoplasms 383Neoplasm Metastasis 370Pancreatic Neoplasms 361Recurrence 347Lymphoma 340Ovarian Neoplasms 322Lung Neoplasms 297Lymphoma, Non-Hodgkin 295Leukemia 287Glioblastoma 275Precursor Cell Lymphoblastic Leukemia-Lymphoma 249Stomach Neoplasms 246Leukemia, Lymphocytic, Chronic, B-Cell 235Carcinoma, Hepatocellular 231Squamous Cell Carcinoma of Head and Neck 219Lymphoma, Large B-Cell, Diffuse 217Myelodysplastic Syndromes 212Carcinoma, Renal Cell 210Lymphoma, Follicular 183Head and Neck Neoplasms 172Brain Neoplasms 169Triple Negative Breast Neoplasms 167Lymphoma, Mantle-Cell 167

Interventions

ranpirnase 1Human Papillomavirus Recombinant Vaccine nonavalent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Interventional × Condylomata Acuminata × Clear all
NCT05087849 2025-10-02

Intralesional HPV Vaccine for Condylomata

University of California, San Francisco

Phase 1/2 Completed
2 enrolled 7 charts

Condylomata Acuminata, Warts

NCT02535104 2018-06-06

Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV)

Tamir Biotechnology, Inc.

Phase 1/2 Completed
70 enrolled

Condylomata Acuminata, Sexually Transmitted Diseases, Papillomavirus Infections

NCT01532102 2018-05-30

Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts

Vaxart

Phase 1/2 Completed
24 enrolled

Condylomata Acuminata, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡